Last reviewed · How we verify
NCT07243340
A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
Phase 1, PHASE2 trial testing Herpes Virus C5252 Injection in Glioma, Malignant in 36 participants. Not yet recruiting.
15 December 2027
Quick facts
| Lead sponsor | ImmVira Pharma Co. Ltd |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 15 December 2025 |
| Primary completion | 15 December 2027 |
| Estimated completion | 15 December 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Herpes Virus C5252 Injection — full drug profile →
Conditions studied
- Glioma, Malignant — all drugs for Glioma, Malignant →
Sponsor
ImmVira Pharma Co. Ltd — full company profile →
Who can join
18 and older, any sex, with Glioma, Malignant. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study includes phase I dose escalation part and phase IIa dose expansion part. The goal of this clinical trial is to learn if C5252 treatment is safe and well tolerated in patients with intracranial tumor and to learn preliminary efficacy of C5252. In this study, participants will be given single or multiple doses of C5252 according to protocol followed by toxicity observation, safety follow-up and long-term follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07243340
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioma, Malignant
Currently open trials in the same condition.
- NCT06917885 — CUE-102 in Recurrent Glioblastoma · Phase 1 · recruiting
- NCT06942104 — Imaging of Solid Tumors Using 18F-TRX · Phase 1 · recruiting
- NCT06169280 — Repeated Neural Stem Cell Based Virotherapy for Newly Diagnosed High Grade Glioma · Phase 1 · recruiting
- NCT06636162 — Window of Opportunity Study of DSP-0390 in Gliomas · EARLY_PHASE1 · recruiting
- NCT06810544 — Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss · Phase 1, PHASE2 · recruiting
Other ImmVira Pharma Co. Ltd trials
Trials by the same sponsor.
- NCT06971614 — A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC · Phase 2 · recruiting
- NCT05756556 — T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma · Phase 2 · suspended
- NCT05095441 — A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma · Phase 1 · not yet recruiting
- NCT04370587 — A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07243340 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by ImmVira Pharma Co. Ltd
- Last refreshed: 21 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07243340.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing